Valeant Pharmaceuticals reported $1.46B in Gross Profit on Sales for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Gross Profit On Sales Change
Amgen AMGN:US USD 5.09B 28M
Ani Pharmaceuticals ANIP:US USD 50.93M 12.37M
Aurora Cannabis Inc ACB:CN CAD -22824000 580K
Biogen BIIB:US USD 2.04B 66.1M
Bristol Myers Squibb BMY:US USD 8.89B 21M
Canopy Growth Corp WEED:CN CAD 3.82M 5.21M
Catalent CTLT:US USD 258M 230M
Corcept Therapeutics CORT:US USD 100.39M 1.68M
Danaher DHR:US USD 4.94B 355M
Drreddys Laboratories RDY:US INR 40.09B 2.85B
Eli Lilly And LLY:US USD 5.75B 391.2M
Endo International Ordinary Shares ENDP:US USD 364.83M 28.49M
Gilead Sciences GILD:US USD 5.99B 346M
Horizon Pharma HZNP:US USD 691.23M 45.03M
Nektar Therapeutics NKTR:US USD 18.65M 2.18M
Pacira Pharmaceuticals PCRX:US USD 116.79M 2M
Perrigo Ordinary Shares PRGO:US USD 362.9M 9.2M
Prestige Brands PBH:US USD 150.4M 10.61M
Revance Therapeutics RVNC:US USD 18.28M 566K
Valeant Pharmaceuticals VRX:CN USD 1.46B 72M
Vertex Pharmaceuticals VRTX:US USD 2.04B 110.5M
Zoetis ZTS:US USD 1.4B 36M